WP6 Laboratory Site Capacity

Laboratory Site Capacity Building

Work package objectives:

The overall goal is to provide ‘state-of-the-art’ laboratory expertise for all vaccine clinical trials in VACCELERATE by building and maintaining a fully operational laboratory network with sites that can be selected for clinical studies with an external quality assessment. Tapping into LAB-Net, an IMI-funded infrastructure within the COMBACTE projects, VACCELERATE will provide access to a Europe-wide network of more than 800 laboratories in 41 countries. The team develops, validates and deploys detection assays for circulating and new SARS-CoV-variants during the clinical vaccination studies and validates and deploys next-generation tests. It provides together with WP5 and WP8 study-specific training to sites selected to participate in clinical studies and assists in finalising clinical protocols by adjusting SOPs, in line with the study objectives for standardised and harmonised sampling. The goal is to perform targeted and whole genome sequencing determination from specimens from vaccinated individuals developing respiratory symptoms. This provides information about evolution of the virus and enables identification of potential virulence markers, and emergence of markers of resistance to vaccination. This work will expand the existing PREPARE and RECOVER biobank with patient informed consent, well-characterised clinical samples collected in clinical vaccine trials for use in further studies.

WP Lead:

Prof. Herman Goossens

University of Antwerp, VAXINFECTIO, Laboratory of Medical Microbiology, Antwerp, Belgium